Global & Managed Access Programs Incremental, Cannibalising Revenue for Biocon A disciplined approach to unlocking underutilised portfolio value in non- core markets while protecting channel integrity and brand positioning.

The Commercial Problem Market Realities Biocon faces margin compression in regulated markets with limited geographic penetration. Under-monetized ANDAs and low-priority SKUs represent stranded value, while core channels approach saturation. Indiscriminate volume expansion risks brand equity degradation and channel conflict. Margin Pressure Regulated markets delivering compressed returns Stranded Assets ANDAs and SKUs generating minimal revenue Channel Saturation Core distribution reaching capacity limits Objective: Unlock incremental revenue without channel conflict or reputational risk

Program Architecture Global Access Program (GAP) Structured access to non-core, underserved global markets through a channel-neutral, export-led model. Focus on geographies outside Biocon's active penetration strategy. Aggregated institutional demand Export compliance from India Zero primary channel interference Managed Access Program (MAP) Controlled market entry with defined scope, pricing governance, and portfolio segmentation. SKU-level control replaces portfolio-wide exposure. Pre-approved markets and price corridors Volume caps and audit readiness Clear exit triggers Strategic positioning: Incremental revenue layer4not a distribution substitute.

GAP Revenue Mechanics

  1. Geographic Selection Target markets where Biocon has no active presence or commercial infrastructure
  2. Demand Aggregation Institutional buyers, not spot market trading4predictable volumes with contracted terms
  3. India-Based Execution CDSCO compliance, export documentation, and quality oversight managed locally
  4. Channel Neutrality No overlap with existing distribution4protects pricing power in core markets Outcome: Monetization of Fresh of the lab molecules or stranded or low- priority SKUs without cannibalizing existing revenue streams or creating margin dilution risk. This strategy unlocks a distinct, sustainable incremental revenue stream by activating dormant assets and offering a superior risk-adjusted return compared to traditional market expansion. It also ensures pricing integrity is preserved within core markets, optimizing overall profitability and market positioning.

Risk Mitigation & Execution MAP Downside Protection SKU-by-SKU and market-by-market approval process Pre-defined price corridors prevent margin erosion Volume caps limit exposure Regulatory ring-fencing maintains audit readiness GNH India Capabilities CDSCO and export compliance execution Regulatory documentation and QA oversight Hard-to-access market experience Transparent commercial structure Commercial positioning: GNH India serves as an execution partner with arm's-length accountability4not a traditional reseller relationship.

Proposed Pilot Structure 335 Non-Core SKUs Low-priority ANDAs with minimal existing revenue contribution Single Geography Defined market with no current Biocon commercial activity Clear Metrics Margin percentage, volume targets, regulatory compliance tracking 90-Day Evaluation Structured decision gate: continue, scale selectively, or exit GNH India enables Biocon to monetize global demand without compromising margin, channel strategy, or reputation. Decision framework: No lock-in commitment. Performance-based scaling with full transparency and control retention at every stage.